PDA Options: To view abstract content with the ability to bookmark to set up an itinerary that you can download and save to your PDA or computer, click on MY ITINERARY in the banner above; then proceed by searching the online database.



Sponsored by
Category Index Expand / Collapse All
Click on one of the following letters below to display a list of alphabetized categories.
Click the checkbox next to each item to bookmark.
A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z
 A


Expand/Collapse Item Adjuvant Chemotherapy
Expand/Collapse Item Adjuvant Endocrine Therapy
Expand/Collapse Item Adjuvant Therapy - Other
Expand/Collapse Item Adjuvant Therapy - Targeted
Expand/Collapse Item Advanced Chemotherapy
Expand/Collapse Item Advanced Endocrine Therapy
Expand/Collapse Item Advanced Therapy - Targeted
Expand/Collapse Item Alternative Therapies
Expand/Collapse Item Angiogenesis
Expand/Collapse Item Animal Models
Expand/Collapse Item Antiangiogenic Therapy (Adjuvant and Metastatic)
  [902] Targeting of chemotherapy to Tie-2-receptor positive angiogenic endothelial cells of tumor vasculature.
  [906] A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer.
  [4113] Preliminary safety results from a multicenter phase II noncomparative two arm pilot of bevacizumab with anastrozole or fulvestrant as 1st line metastatic breast cancer therapy.
  [4114] Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cancer.
  [4115] Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.
  [4116] Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.
  [4117] Phase 1b study of motesanib diphosphate (AMG 706) in combination with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer.
  [4118] Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC).
  [4119] Phase I study of sunitinib in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer.
  [4120] Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer.
  [4121] Bevacizumab (BEV) and paclitaxel (PAC) every two weeks as first-line treatment for advanced breast cancer (ABC). Preliminary results.
 
 

Abstract Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved